Treatment with oral desmopressin in adolescents with primary nocturnal enuresis. Efficacy and long-term effect.
Twenty-four adolescents, mean age 13.5 years, with primary nocturnal enuresis (PNE), were studied to evaluate the efficacy of long-term oral desmopressin use. Reduction in mean number of wet nights per week was the criterion for response. Results showed that during 12-week treatment Period I, 48% were full responders (< or = 1 wet night/wk); 22% were intermediate responders (2 to 3 wet nights/wk); and 30% were nonresponders (> 3 wet nights/wk). During 12-week treatment Period II, 53% were full responders, 23.5% were intermediate responders, and 23.5% were nonresponders. Despite a high relapse rate (50% after Period I, 56% after Period II), 17 patients (71%) were completely dry 2 years posttreatment, suggesting a possible curative effect of oral desmopressin. It was concluded that oral desmopressin is comparable to the intranasal formulation, with a good, long-term therapeutic effect in adolescents with PNE.
Department of Pediatric Surgery, Uppsala University Children's Hospital, Sweden.
A
A
Stenberg
G
G
Läckgren
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000627:therapeutic use*; D004775:Enuresis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D012107:Research Design; D012449:Safety; D016037:Single-Blind Method
D003894:Deamino Arginine Vasopressin